Company Analysis
Sign in

Entrada Therapeutics, Inc. (TRDA)

Nasdaq: TRDA · Pharmaceutical Preparations · Boston, MA · filing with the SEC since 2016
Full chart Alerts Compare
Grade5.2
◀ Past 5.9● Present 4.9▶ Future 5.0
2 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

The grade of Entrada Therapeutics, Inc.

Nine metrics read from its own filings, by tense
Headline grade
5.2/10
◀ Past5.930% of the headline
● Present4.940% of the headline
▶ Future5.030% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 7 read as filed from the record and 2 are SI estimates, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

5.9/1030% of the headline grade · 2 of 3 filed, 1 estimated

Surviving crises

as filed
8.2/10

Has it survived what it has been through?

No warning events in its filings since 2017.

weight 33% of this tense · 82nd percentile among 497 sector filers · read for itself

From the record

Entrada Therapeutics, Inc.'s filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed
3.9/10

What has it actually done, year after year?

-55.6% a year over 3 filed years; profitable in 1 of 3.

weight 45% of this tense · 39th percentile among 323 sector filers · read for its customers

From the record

Entrada Therapeutics, Inc.'s 3 filed years say what it did: revenue went from $129 million in fiscal 2023 to $25 million in fiscal 2025, down 55.6% a year; it rose in 1 of 2 years; the deepest fall was 88% from fiscal 2024 to fiscal 2025; net income was positive in 1 of 3 of those years (its annual reports).

What it rests on

  • revenue growth over the filed span-55.6%bottom 2% of its family
  • the share of years revenue rosebottom 36% of its family
  • the share of filed years with a profittop 19% of its family
  • the deepest fall from a revenue peak87.9%bottom 36% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

SI estimate
6.5/10

How has it treated the people who own it?

SI estimate 6.5/10, confidence 35 of 100 (one part).

weight 22% of this tense · 65th percentile among 464 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate
Read from one part only, the share count over the years, which ranks in the top 35% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
What the record cannot read
Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
How it was reasoned
one part: the share count over the years, the one part on file, ranked among 464 in its family.
Confidence
35 of 100
What would change it
A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Entrada Therapeutics, Inc.'s shareholder treatment is put at 6.5 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the top 35% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.

● Present

What are they doing right now?

4.9/1040% of the headline grade · 3 of 3 filed

Financial health

as filed
6.4/10

Is it financially healthy right now?

ROE -47%: lost 47¢ per shareholder dollar. Leverage 19%: owes 19¢ per asset dollar.

weight 45% of this tense · 64th percentile among 473 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2025-12-31, Entrada Therapeutics, Inc. lost about 47 cents for every dollar of shareholders' money. Leverage: it owed about 19 cents per dollar of assets, and net share issuance: its share count grew 6.1% over the year (the filed statements).

What it rests on

  • what it owes per dollar of assetstop 30% of its family
  • return on equitytop 47% of its family
  • the share count against the year beforetop 32% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

as filed
3.0/10

How strong is its position in its industry?

bottom 30% of 315 in its family; net margin -565.5%.

weight 33% of this tense · 30th percentile among 315 sector filers · read for its customers

From the record

Entrada Therapeutics, Inc.'s standing among 315 graded names in its industry family: revenue of $25 million in fiscal 2025 ranks in the bottom 48% by size; a net margin of -565.5% ranks in the bottom 36%; revenue growth of -55.6% a year over the last 2 filed years ranks in the bottom 6% (its annual reports).

What it rests on

  • revenue against the family$25.4Mbottom 48% of its family
  • net margin-565.5%bottom 36% of its family
  • three-year revenue growth-55.6%bottom 6% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

as filed
4.9/10

What are the people in charge doing?

bottom 49% of 315 in its family for leadership; chief executive since 2021.

weight 22% of this tense · 49th percentile among 315 sector filers · read for its shareholders

From the record

Entrada Therapeutics, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Doshi, Dipal (CEO, as filed), filing under that title since 2021-10-28, 5 years (bottom 48% of its family); the 11 officers and directors filing in the last fifteen months have been on the record a median of 5 years (bottom 36%); 4 officer or director changes were reported on Form 8-K since 2023-11-13, against the 11 people in charge now (top 37%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

What it rests on

  • officer and director changes on Form 8-K, against the people in charge4 in three years among 11 peopletop 37% of its family
  • the median years the people in charge have filed5.0 yearsbottom 36% of its family
  • the chief executive's years on the record5.0 yearsbottom 48% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

▶ Future

What are they set up to do next?

5.0/1030% of the headline grade · 2 of 3 filed, 1 estimated

Room to expand

as filed
5.1/10

How much room does it have to grow?

top 49% of 273 in its family for room to expand.

weight 45% of this tense · 51st percentile among 273 sector filers · read for itself

From the record

Entrada Therapeutics, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $94 million against no long-term debt tagged leaves 25% of its assets as net cash, bottom 47% of its family; cash from operations less capital spending is -509.6% of revenue (bottom 34%); research spending of 559.7% of revenue (top 27%) (its annual report).

What it rests on

  • cash less debt against assets25.0%bottom 47% of its family
  • cash from operations less capital spending against revenue-509.6%bottom 34% of its family
  • research spending against revenue559.7%top 27% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Growth drivers

as filed
4.7/10

What could actually drive growth from here?

bottom 47% of 306 in its family for growth drivers.

weight 33% of this tense · 47th percentile among 306 sector filers · read for its customers

From the record

Entrada Therapeutics, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew -55.6% a year over the last three filed years against -55.6% over all 3, speeding up (top 40% of its family); the newest year grew -88% (bottom 4%); research spending grew 28.8% a year (top 16%); capital spending grew -28.8% a year (bottom 39%) (its annual reports). Entrada Therapeutics, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

What it rests on

  • three-year growth against the whole span+0.0 points a yeartop 40% of its family
  • the newest year's revenue growth-88.0%bottom 4% of its family
  • three-year growth of research spending28.8%top 16% of its family
  • three-year growth of capital spending-28.8%bottom 39% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Expectations vs reality

SI estimate
5.3/10

Did its newest year beat what its own record pointed to?

SI estimate 5.3/10, confidence 20 of 100 (family median).

weight 22% of this tense · 50th percentile among 234 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate
The record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change, so the desk assumes the typical reading of its industry family, the median of 234 members with one.
What the record cannot read
The record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change.
How it was reasoned
family median, 234 readings behind it.
Confidence
20 of 100
What would change it
Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Entrada Therapeutics, Inc.'s expectations vs reality is put at 5.3 of 10 with a confidence of 20 of 100, because the record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change, so the desk assumes the typical reading of its industry family, the median of 234 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton TRDA · research, not advice